We then investigated whether excessive IL-11 could induce drug resistance to oxaliplatin, and the results showed that an addition of IL-11 partially reversed the efficacy of oxaliplatin-mediated inhibition of cell viability in colon cancer cells (Fig. 6a). The gene discussed is IL11; the disease is colonic neoplasm.